Bringing natural killer cells to the clinic: ex vivo manipulation

Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy

(2013) Y. Liu et al.   CLINICAL CANCER RESEARCH

Immunomodulatory therapy for melanoma: Ipilimumab and beyond

(2013) Margaret K. Callahan et al.   CLINICS IN DERMATOLOGY

Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers

(2013) Eun-Kyung Kim et al.   CYTOTHERAPY

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling

(2013) Erik Wennerberg et al.   INTERNATIONAL JOURNAL OF CANCER

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

(2013) Stefania Laurent et al.   Journal of Translational Medicine

NK Cells—From Bench to Clinic

(2012) William J. Murphy et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7

(2012) S. S. Somanchi et al.   BLOOD

Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers

(2012) M Stern et al.   BONE MARROW TRANSPLANTATION

Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy

(2012) Martha Luevano et al.   Cellular & Molecular Immunology

Natural killer cell alloreactivity 10 years later

(2012) Andrea Velardi   CURRENT OPINION IN HEMATOLOGY

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

(2012) Natalia Lapteva et al.   CYTOTHERAPY

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

(2012) Noriko Shimasaki et al.   CYTOTHERAPY

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

(2012) T. K. Garg et al.   HAEMATOLOGICA

Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy

(2012) Tolga Sutlu et al.   HUMAN GENE THERAPY

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

(2012) Cecele J. Denman et al.   PLoS One

Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products

(2012) Robert Skeate et al.   TRANSFUSION

Natural Killer Cell Differentiation from Hematopoietic Stem Cells: A Comparative Analysis of Heparin- and Stromal Cell–Supported Methods

(2011) Steven A. Dezell et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

(2011) A. Curti et al.   BLOOD

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

(2011) D. M. Benson et al.   BLOOD

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

(2011) M. R. Parkhurst et al.   CLINICAL CANCER RESEARCH

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

(2011) Laurent Boissel et al.   LEUKEMIA & LYMPHOMA

Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process

(2011) Jan Spanholtz et al.   PLoS One

Natural killer cell engineering for cellular therapy of cancer

(2011) D. R. Shook et al.   TISSUE ANTIGENS

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Allogeneic natural killer cells for refractory lymphoma

(2010) Veronika Bachanova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

(2010) Uwe Siegler et al.   CYTOTHERAPY

Ex-vivo expansion of NK cells: What is the priority - high yield or high purity?

(2010) Maria Berg et al.   CYTOTHERAPY

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

(2010) Tolga Sutlu et al.   CYTOTHERAPY

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity

(2010) Caroline J Voskens et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity

(2009) P. S. Woll et al.   BLOOD

Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells

(2009) A. Lundqvist et al.   BLOOD

Replicative potential of human natural killer cells

(2009) Hiroyuki Fujisaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells

(2009) B. Altvater et al.   CLINICAL CANCER RESEARCH

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

(2009) Maria Berg et al.   CYTOTHERAPY

Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells

(2009) A. Lundqvist et al.   JOURNAL OF IMMUNOLOGY

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

(2008) E. Alici et al.   BLOOD

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural killer cell immunotherapy for cancer: a new hope

(2008) S. Srivastava et al.   CYTOTHERAPY

Permanent silencing of NKG2A expression for cell-based therapeutics

(2008) Constança Figueiredo et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone

(2008) Robert Sackstein et al.   NATURE MEDICINE

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

(2008) A. Kruschinski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA